AbbVie Raises 2026 Outlook, Boosts Dividend
AbbVie hits a new 52-week high after beating Q3 2026 earnings estimates, raising its full-year guidance, and boosting its dividend.
Stocks · News reference
Conference call: AbbVie Sees Q4 Adj EPS $3.83-$3.87 vs $3.89 Est; Sees Sales $18.400B vs $18.300B Est
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
CNBC Halftime Report Final Trades: eBay, FTAI Aviation, AbbVie, Goldman Sachs Nasdaq-100 Premium Income ETF
Defensives Lead Sectors In Friday Trading As Growth Trails
Five sectors are higher and six are lower in Friday's regular session, with defensive sectors holding the top three positions. The leaders are clustered rather than separated, while Technology sits well clear of the rest, divided from the next-weakest sector by a margin several times wider than any other gap.
Conference call: AbbVie Raises FY2026 Sales Guidance from $67.600B to $67.800B vs $67.585B Est
AbbVie Reports Third-Quarter 2026 Financial Results and Increases Dividend
AbbVie reported third-quarter 2026 financial results, exceeding analyst expectations, and raised its full-year 2026 adjusted earnings guidance while announcing a 5.2% dividend increase.
AbbVie Raises FY2026 Adj EPS Guidance from $13.76-$13.96 to $13.95-$13.99 vs $13.93 Est